Cancer patients are highly susceptible to thromboembolic complications, which some have
estimated accounts for a significant percentage of the morbidity and mortality of the disease …

The “hypercoagulable state” of malignancy is due to a complex interaction of tumor cells and
their products with host cells, leading to various degrees of impairment of the normal …

Nearly all patients with cancer manifest laboratory evidence of hypercoagulability and some
develop clinical thromboembolic disease (TED). Routine laboratory studies of blood …

CUTE PROMYELOCYTIC leukemia (APL) is a dis-A tinct variety (French-American-British
M3) of acute myelogenous leukemia (AML) distinguished by the presence of a balanced …

Thrombocytopenia is a frequent complication of cancer and its treatment. The causes of
thrombocytopenia in cancer patients can be diverse and multifactorial. Systemic …

ACUTE PROMYELOCYTIC leukemia (APL) is a distinct subtype of acute myelogenous
leukemia (AML), identified by the French-American-British classification as AML-M31 and …

There is strong evidence linking venous thromboembolic events and malignancy.
Laboratory markers of coagulation activation such as thrombin–antithrombin complex or …

Tissue factor is a cell surface glycoprotein responsible for initiating the extrinsic pathway of
coagulation. Many tumor cell homogenates and intact tumor cells have been shown to …

Since the initial description of the disease, the life-threatening coagulopathy associated with
acute promyelocytic leukaemia (APL) has been the defining clinical characteristic …

Malignancy is associated with a``hypercoagulable''state and a high risk for
thrombohemorrhagic complications. Clinical complications may range from localized …